This is a UK news story, published by Yahoo, that relates primarily to Pfizer news.
For more UK news, you can click here:
more UK newsFor more Pfizer news, you can click here:
more Pfizer newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Novo Holdings. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest latest funding round news, Novo Nordisk news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
olorofimReuters
•80% Informative
F2G said on Thursday it has raised $100 million from investors including large drugmakers such as Johnson & Johnson and Pfizer .
The funding also includes investment from Novo Holdings that holds a controlling stake in Novo Nordisk .
The latest round would help the UK -based company complete a global late-stage study of its lead drug, olorofim.
The U.S. Food and Drug Administration rejected the drug last year , citing the need for more data after a mid-stage trial.
VR Score
91
Informative language
97
Neutral language
68
Article tone
formal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links